Objective：To evaluate the efficiency and safety of haploidentical hematopoietic stem cell transplantation（haplo-HSCT）for treatment of secondary myelodysplastic syndrome（sMDS） after AA. Methods：Evaluation of therapeutic effect，incidence rate of aGVHD and cGVHD，complications and overall survival（OS） of 5 AA post MDS patients who received haplo-HSCT in this center，and compared with other treatments for sMDS evolved from AA. Results：Among 5 patients，median OS was 63 months（range from 41.9 to 149.3 months），OS after HSCT was 12.9 months（range from 2.4 to 36.5 months）. 1-year event free survival was 60%. All patients achieved neutrophil and platelet engraftment at a median of 18 days（range from 14 to 22 days）and 21 days（range from 15 to 65 days）respectively. 3 occurred Ⅰ~Ⅲ° acute graft versus host disease（aGVHD），and 1 with chronic graft versus host disease（cGVHD）. Medial follow-up was 63 months（range from 41.9 to 149.3 months）. Conclusion：The haplo-HSCT can be an opition for sMDS from AA patients in case of an HLA-identical donor is not available.